QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.050583v1 306/2/638    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Summers, M. A. Articles by Goetzl, E. J. Search for Related Content PubMed PubMed Citation Articles by Summers, M. A. Articles by Goetzl, E. J.

INFLAMMATION AND IMMUNOPHARMACOLOGY

A Lymphocyte-Generated Fragment of Vasoactive Intestinal Peptide with VPAC1 Agonist Activity and VPAC2 Antagonist Effects

Depaertment of Pediatrics, University of Iowa, Iowa City, Iowa (M.A.S., M.S.O., M.O.C., M.L.-M.); and Departments of Medicine and Microbiology-Immunology, University of California, San Francisco, California (E.J.G.)

Vasoactive intestinal peptide receptors 1 (VPAC1) and 2 (VPAC2) have been identified in humans. Cell lines expressing only VPAC1 (HT-29) or VPAC2 (Molt-4b) were identified using real-time reverse transcriptase polymerase chain reaction. Vasoactive intestinal peptide (VIP) and related peptides, VIP_–6–28, VIP_4–28, and VIP_10–28, previously isolated from cultures of human leukocytes, were evaluated for their ability to bind to VPAC1 and VPAC2 and to increase the levels of cAMP in HT-29 and Molt-4b cells. VIP bound to membranes of HT-29 colon carcinoma cells and Molt-4b lymphoblasts with high affinity (K_D = 1.6 ± 0.2 and 1.7 ± 0.9 nM, respectively). VIP_4–28 also demonstrated high-affinity binding (K_D = 1.7 ± 0.2 and 1.7 ± 0.7 nM in HT-29 and Molt-4b, respectively). VIP and VIP_4–28 are potent VPAC1 agonists, inducing maximal 200- and 400-fold increases in cAMP, respectively. VIP demonstrated weak VPAC2 agonist activity, inducing a maximal 14-fold increase in cAMP. VIP_4–28 had no VPAC2 agonist activity but demonstrated potent VPAC2 antagonist activity. VIP_4–28 inhibited VPAC2-mediated increases in cAMP in Molt-4b cells up to 95%, but had no antagonistic effect on VPAC1. Lymphoblasts did not hydrolyze VIP_4–28 to a form with VPAC1 antagonist activity. VIP_4–28 thus is a lymphocyte-generated VIP fragment with potent agonist activity for VPAC1 and potent antagonist activity for VPAC2.

Address correspondence to: Dr. M. Sue O'Dorisio, Department of Pediatrics, 2520 JCP, 200 Hawkins Dr., Iowa City, IA 52242. E-mail: sue-odorisio{at}uiowa.edu

This article has been cited by other articles:

				D. Fabricius, M. S. O'Dorisio, S. Blackwell, and B. Jahrsdorfer Human Plasmacytoid Dendritic Cell Function: Inhibition of IFN-{alpha} Secretion and Modulation of Immune Phenotype by Vasoactive Intestinal Peptide J. Immunol., November 1, 2006; 177(9): 5920 - 5927. [Abstract] [Full Text] [PDF]

				M. Delgado, D. Pozo, and D. Ganea The Significance of Vasoactive Intestinal Peptide in Immunomodulation Pharmacol. Rev., June 1, 2004; 56(2): 249 - 290. [Abstract] [Full Text] [PDF]